Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 30,939 shares, an increase of 138.0% from the October 15th total of 13,000 shares. Based on an average daily volume of 5,135 shares, the short-interest ratio is currently 6.0 days.
Innovent Biologics Stock Down 0.0%
IVBXF stock traded down $0.00 during mid-day trading on Friday, reaching $11.08. The company had a trading volume of 831 shares, compared to its average volume of 3,616. The stock has a 50 day simple moving average of $11.88 and a two-hundred day simple moving average of $11.23. Innovent Biologics has a 52 week low of $9.10 and a 52 week high of $15.01.
About Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. The company primarily targets oncology, autoimmune, cardiovascular and metabolic diseases, with an emphasis on biologic therapies, biosimilars and other specialty treatments. Its marketed and development portfolio includes therapies such as TYVYT (sintilimab), a PD-1 inhibitor developed in collaboration with Eli Lilly, as well as products based on or related to bevacizumab, rituximab and adalimumab.
Further Reading
- Five stocks we like better than Innovent Biologics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
